Mendaera announced its handheld robot for needle-based procedures is now available to pair with Butterfly Network’s (NYSE:BFLY) portable, chip-based ultrasound probe, following the companies’ long-running collaboration.
A new study led by researchers from the Icahn School of Medicine at Mount Sinai and published in Brain Communications found that a transcranial low-amplitude magnetic field intervention delivered twice weekly into the brain through a noninvasive headset was associated with improvements in several measures of cognitive function and emotional well-being in people experiencing cognitive impairment associated with long COVID.
MARLBOROUGH, Mass., Oct. 1, 2026 /PRNewswire/ — BTL Industries, a global leader in medical and wellness technologies, today announced expanded FDA clearances for EXOMIND®, its noninvasive brain stimulation platform.
Medtronic plans to study the device in patients with peripheral artery disease below the knee, a historically difficult condition to treat.
Edwards Lifesciences earned FDA approval for its Autus size-adjustable heart valve, a surgical pulmonary heart valve for pediatric patients with congenital heart disease, the company announced today.
Researchers at the Icahn School of Medicine at Mount Sinai have developed an artificial intelligence (AI) approach that uses data from wearable devices to forecast upcoming periods of prolonged sitting in women with chronic pelvic pain disorders.
A new Yale-developed artificial intelligence (AI) platform can detect individuals at risk for amyloid cardiomyopathy, an underdiagnosed cardiac condition, using data from a quick and accessible heart test.
A team led by University of Massachusetts Amherst researchers has developed a wearable wrist device powered by a machine-learning algorithm that can continuously track changes in arm movement impairment after a stroke. Monitoring those changes throughout rehabilitation could allow clinicians to adjust therapy in real time, tailoring care instead of relying on the current one-size-fits-all approach.
ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average risk for the disease.
HCTI signs MOU which details planned North American Joint Venture.The Proposed venture would deploy humanoid robots to assist with patient toileting and hygiene care, easing the physical burden on nursing teams while preserving patient dignity